Price $35.73 · Base $13.65 · Price is +162% above base
Price (10/14 intraday)
$35.73
Base intrinsic value
$13.65
Bear → Blue-sky range
$8 – $33
Key driver
Steady-state GAAP margin; price needs ~42%
The Take — Avoid. This is a directed-energy lottery ticket priced as if it already paid out.
The business has never made a GAAP operating profit. Five straight years of net losses ($-24M to $-61M), revenue in 2025 ($261M) still below 2021 ($270M). The Q2-26 "record" was a $3.6M operating loss; the $10.7M adjusted EBITDA exists only because ~$11M/quarter of stock comp is added back. SBC is running ~14% of revenue — that is a real cost, paid in dilution: diluted share count went from ~49M to ~58–60M in 18 months, including a $175M offering at $44 in February.
Even generous assumptions don't reach the price. Base case grows revenue 20%/18%/15% on the JLWS ramp, reaches $820M by 2036 and a 14% GAAP EBIT margin (a level the company has never touched) — that's worth $13.65, of which ~$5.30 is cash. A bull case with ~$1.2B revenue and 20% margins gets $23.16. Even a blue-sky case — $1.67B revenue (5x today) at 22% margins, i.e. nLight becomes the HEL weapons prime — prints $32.87, still under today's quote.
The reverse DCF is the cleanest indictment: at the base growth path the price requires a ~42% steady-state GAAP operating margin (IPG at its 2017 peak did ~37% with minimal SBC drag); at a 14% margin it requires ~2.9x the base-case growth rates every year for a decade. The market isn't valuing a laser company — it's pricing an option on laser weapons becoming a multi-billion program of record, with nLight capturing most of it.
Near-term tape is also against you: Q3 guide ($63–73M, GM 24–30%) is a sequential step-down on ~$17M of product deferred by Chinese optics supply (China tightening dual-use scrutiny — "months to quarters" to fix). HELSI-2 rolls off late 2026; JLWS ($44M initially funded of a $600M+ ceiling) must fill the hole. Insiders sold ~$27M over 90 days (CEO 100k sh at $41 on 9/9, 10b5-1). Stock is below its 50-dma ($45) and 200-dma ($61), down 59% from the May high.
Call: No new money above ~$20. Holders: trim into any JLWS/HEL headline pop. Value accumulation only <$15 (≈ base value, with cash cushion). Speculators who want the DE option: cap at ≤0.5% of capital and accept it can halve again. If expressing the bear view, do it defined-risk — a post-earnings bear call spread above ~$50 (the 50-dma/gap zone) — never naked short: beta 2.4, and a single DoD award headline can gap it +25%. Q3 print Nov 5 after close; IV will be rich into it.
Risk Profile — VERY HIGH
HIGH
Program/contract concentration — revenue rides a handful of DoD HEL programs (HELSI-2 ending, JLWS starting, DE M-SHORAD). Long: defense budget for directed energy; short: program delays, CRs, recompetes.
HIGH
Supply chain / China — commodity optics sourced from China now held up by dual-use scrutiny; $17M of Q3 product deferred. Short: China export posture.
HIGH
Dilution / SBC — ~$43M TTM SBC (14% of rev) + Feb-26 equity raise. Per-share value erodes even if the enterprise grows.
MED
Development-mix margin — development (cost-plus) revenue earns ~5–8% GM vs ~41% product; JLWS early phases skew to development, capping 2027 margins.
MED
Commercial cyclicality — industrial/microfab (~30%) faces Chinese fiber-laser price competition (Raycus et al.).
LOW
Balance sheet — $331M cash/investments, revolver repaid, no funded debt. The one genuinely solid line: no solvency risk.
What the "inventory" really is: a DoD development book (cost-plus, thin margin) plus an option on production-rate laser weapons. The DCF assigns the option almost nothing until it converts to product revenue at scale — that conversion is the entire debate.
No single assumption swing gets within $19/share of the price. Margin is the widest bar — the investment is a bet on steady-state profitability that hasn't yet existed.
Every cell is red (>15% below price). Price is outside the grid entirely.
History — revenue vs net income ($M)
Blue = revenue, red = net loss. Normalization worksheet below: 5-yr avg adj. EBIT is negative, so the ginzu engine collapses to net cash; the growth DCF is run alongside to give the bull narrative full credit.
GAAP EBIT from 10-K XBRL (SEC). R&D capitalized on a 5-yr straight-line life (FY2016–25 R&D from XBRL); Adj. EBIT = EBIT + R&D − amortization; research asset $145M added to invested capital. FCF = OCF − capex. SBC kept as an operating expense (Damodaran) — it is not added back anywhere.
What normalization says. 5-yr average R&D-adjusted EBIT is −$33M (−15% margin). Through the full 2017–2025 cycle: 2017: 15.8%, 2018: 16.7%, 2019: 4.5%, 2020: 1.9%, 2021: 0.2%, 2022: -13.8%, 2023: -19.2%, 2024: -32.9%, 2025: -10.2% — average -4.1%. Capitalizing R&D barely helps today because spend has been flat at ~$45–55M since 2021, so amortization (~$50M) ≈ current R&D. The only profitable years were the 2017–18 Chinese fiber-laser boom (adj. ~16%).
Four lenses, one answer:
5-yr normalized (ginzu) → operating value ≤ 0 → equity ≈ net cash $5.26 ·
Full-cycle normalized (−4.1%) → same cash floor $5.26 ·
Best-ever adj. margin (16.2%) on TTM revenue, no growth → $11.23 ·
Growth DCF (base) → $13.65. None comes within 60% of $35.73.
FCF reality: 5-yr cumulative FCF −$56M; after SBC −$205M. The TTM +$42M FCF is $11M working-capital release plus $43M of SBC paid in stock — strip SBC and it's −$1M.
Base case on an R&D-capitalized basis (consistency check)
Year
R&D
Amort
Adj. EBIT
Adj. margin
Invested capital
Adj. after-tax ROIC
2027
59.5
48.7
8.6
2.3%
301
2.9%
2028
67.4
49.9
25.9
5.8%
342
7.6%
2029
74.4
54.1
42.3
8.2%
384
11.0%
2030
79.8
60.0
58.5
10.2%
435
12.1%
2031
83.9
66.3
75.5
11.9%
481
14.1%
2032
86.4
73.0
92.6
13.5%
520
14.1%
2033
87.5
78.4
111.2
15.3%
551
15.9%
2034
91.9
82.4
116.7
15.2%
579
15.9%
2035
95.6
85.9
121.2
15.2%
604
15.8%
2036
98.4
89.0
124.2
15.1%
626
15.7%
R&D fades from 16.3% to 12% of revenue. FCFF is identical either way (net R&D capex is added to both adj. EBIT and reinvestment), so value doesn't move — but the check matters: the base case already assumes adj. margins of ~15% (≈ the 2017–18 peak) and ROIC rising to ~16% vs a 12% terminal assumption. Base is not a haircut; it's "return to the best years and stay there."